Amicus Therapeutics' stock experienced a significant plummet of 7.51% in the pre-market trading session on Wednesday. This downward movement came after the company reported its fourth-quarter earnings results, which fell short of market expectations.
According to the earnings report, Amicus Therapeutics reported earnings per share (EPS) of $0.09, missing the Zacks Consensus Estimate of $0.10 per share. Additionally, the company's quarterly revenue of $149.71 million narrowly missed the consensus estimate of $149.88 million.
The disappointing earnings results raised concerns among investors, leading to the substantial sell-off in the pre-market session. Analysts suggest that the company's performance and future outlook will be closely scrutinized during the upcoming earnings call, which may provide further insights into the stock's price movement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.